Lisa H. Downs
University of Pennsylvania
22 Papers
108 Citations
Lisa H. Downs is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Lymphoma & Follicular lymphoma. The author has an hindex of 9, co-authored 21 publications. Previous affiliations of Lisa H. Downs include Hospital of the University of Pennsylvania.
Chat about Author
Papers
Utility of FDG-PET scanning in lymphoma by WHO classification
Rebecca Elstrom,Liang Guan,Gary Baker,Khozaim Nakhoda,Jo-Anne Vergilio,Hongming Zhuang,Stephanie Pitsilos,Adam Bagg,Lisa H. Downs,Amit K Mehrotra,Scott Kim,Abass Alavi,Stephen J. Schuster +12 more
TL;DR: Comparison with bone marrow biopsies showed that FDG-PET was not reliable for detection of bone marrow involvement in any lymphoma subtype.
440
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
Jakub Svoboda,Charalambos Andreadis,Rebecca Elstrom,Elise A. Chong,Lisa H. Downs,Arnold Berkowitz,Selina M. Luger,David L. Porter,Sunita D. Nasta,Donald E. Tsai,Alison W. Loren,Don L. Siegel,Eli Glatstein,Abass Alavi,Edward A. Stadtmauer,Stephen J. Schuster +15 more
TL;DR: A retrospective analysis of 50 lymphoma patients who had an 18F-fluoro-deoxyglucose positron emission tomography scan after at least two cycles of salvage chemotherapy and before autologous stem cell transplantation (ASCT) indicated an extremely poor chance of durable response after ASCT.
93
Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection.
Jakub Svoboda,Charalambos Andreadis,Lisa H. Downs,Wallace T. Miller,Donald E. Tsai,Stephen J. Schuster +5 more
TL;DR: This is an example of a patient in whom treatment of HCV infection led to regression of non-splenic, extranodal marginal zone lymphoma, and it suggests that HCV testing and treatment should be considered in all patients with marginal zones lymphomas, including non- splenic types.
31
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma
Charalambos Andreadis,Stephen J. Schuster,Elise A. Chong,Jakub Svoboda,Selina M. Luger,David L. Porter,Donald E. Tsai,Sunita D. Nasta,Rebecca Elstrom,S.C. Goldstein,Lisa H. Downs,Patricia A. Mangan,Kathleen Cunningham,Kimberly Hummel,Phyllis A. Gimotty,Don L. Siegel,Eli Glatstein,Edward A. Stadtmauer +17 more
TL;DR: High-dose chemo/radiotherapy followed by autologous stem-cell transplantation (ASCT) can improve response rates, although its effects on survival remain controversial, resulting in long-term EFS and OS for some patients, even with transformed disease.
29